MedTrace Logo

ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer

NCT05245760 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-11-08

No results posted yet for this study

Summary

This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.

Conditions

  • Esophageal Cancer
  • Esophagogastric Junction Cancer

Interventions

DRUG

Intravenous Tislelizumab

Participants will receive 200mg, every three weeks for up to 51 weeks

DRUG

Chemotherapy

Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks

RADIATION

Fractionated radiation

Concurrent with chemo, x5 weeks

PROCEDURE

Esophagectomy

Surgical resection of cancer after chemoradiation therapy when no disease progression found.

Sponsors & Collaborators

  • BeiGene

    collaborator INDUSTRY

  • University of Kentucky

    collaborator OTHER

  • Zhonglin Hao

    lead OTHER

Principal Investigators

  • Zhonglin Hao, MD, PhD · University of Kentucky

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-30
Primary Completion
2023-03-31
Completion
2033-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05245760 on ClinicalTrials.gov